Psychopharmacology’s ‘Golden Era’ of the 1990s and early 2000s is over. The soaring placebo response rate combined with the lack of novel validated drug targets has ended it. Big Pharma have now largely abandoned psychiatry. The first ‘Golden Era’ of Psychopharmacology in the 1960s and 1970s ended when the therapeutic targets of that era became saturated, and not because the placebo response rate skyrocketed. Innovation was rejuvenated into a second ‘Golden Era’ by agents with fewer side-effects, not really by novel targets, yet on the back of a clinical testing methodology that robustly and consistently distinguished active agents from placebo. Will there be a third ‘Golden Era?’ Indeed, there is hope that academia and small pharma will find the novel targets for the future, but how can innovation be rejuvenated into a third ‘Golden Era’ with novel targets if we cannot tell active agents from placebo?

中文翻译：

---

安慰剂反应率正在破坏精神病学的药物开发：为什么会发生这种情况，我们能做些什么？

1990 年代和 2000 年代初的精神药理学“黄金时代”已经结束。飙升的安慰剂反应率加上缺乏新的经过验证的药物靶点已经结束了。大型制药公司现在基本上已经放弃了精神病学。1960 年代和 1970 年代精神药理学的第一个“黄金时代”在那个时代的治疗目标饱和时结束，而不是因为安慰剂反应率飙升。创新通过副作用更少的药物重新进入第二个“黄金时代”，而不是真正通过新的靶点，而是在临床测试方法的支持下，该方法有力且一致地将活性药物与安慰剂区分开来。会出现第三个“黄金时代”吗？事实上，学术界和小型制药公司有希望找到未来的新目标，